RMTI Rockwell Medical, Inc. - Common Stock
$7,58
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 13, 2026
52W-Spanne
$1–$8
95% of range
Analystenbewertung
BUY
8 analysts
Kursziel
$30
+296% upside
P/E (TTM)
-5.1
ROE
-15.8%
Nettogewinnmarge
-7.7%
Über Rockwell Medical, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Mehr lesen
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
RMTI Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$7.58
Marktkapitalisierung
$30M
P/E (TTM)
-5.1
EPS (TTM)
$-0.15
Umsatz (TTM)
$69M
Dividendenrendite
—
ROE
-15.8%
Verschuldungsgrad
0.2
52W-Spanne
$1 – $8
RMTI Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$69M
2016-12-31
→
2025-12-31
EPS
$-0.15
2016-12-31
→
2025-12-31
Freier Cashflow
$-1M
2024-12-31
→
2025-12-31
Margen
-7.7%
2016-12-31
→
2025-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
RMTI
Peer-Median
P/E (TTM)
-5.1
15.4
P/S (TTM) (K/V (TTM))
0.4
2.8
P/B (K/B)
0.8
1.6
EV / EBITDA
-11.2
—
Price / FCF (Kurs / FCF)
-24.9
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
RMTI
Peer-Median
Gross Margin (Bruttogewinnmarge)
16.9%
31.6%
Operating Margin (Betriebsgewinnmarge)
-6.8%
—
Net Profit Margin (Nettogewinnmarge)
-7.7%
-49.3%
ROA
-9.1%
-54.9%
ROE
-15.8%
-98.0%
ROIC
-10.2%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
RMTI
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
0.2
0.0
Current Ratio (Liquiditätsgrad)
4.0
4.7
Quick Ratio
2.0
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
RMTI
Peer-Median
Revenue YoY (Umsatz YoY)
-31.8%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
-1.7%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
2.2%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
RMTI
Peer-Median
RMTI Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
8 Analysten
- Starker Kauf 2 25,0%
- Kauf 5 62,5%
- Halten 1 12,5%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
2 Analysten · 2026-08-15
Median
$30.00
← Unter allen Zielen
$7.58
Tief
$20.00
Hoch
$40.00
Median-Ziel
$30.00
+295,8%
Mittelwert-Ziel
$30.00
+295,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.09%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.34 | $-0.24 | -0.10% |
| 31. März 2026 | $-0.40 | $-0.26 | -0.14% |
| 31. Dezember 2025 | $-0.10 | $0.20 | -0.30% |
| 30. September 2025 | $-0.50 | $-0.46 | -0.04% |
| 30. Juni 2025 | $-0.50 | $-0.51 | 0.01% |
| 31. März 2025 | $-0.04 | $-0.05 | 0.01% |
| 31. Dezember 2024 | $-0.02 | $0.02 | -0.04% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| ADVB | $15M | -4.4 | — | — | -159.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Bilanz 29
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Cashflow 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Rentabilität 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -60,272,092 | 31,551,805 | 30,451,622 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -62,722,609 | 32,420,168 | 32,033,776 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Bilanz 26
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Cashflow 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Rentabilität 6
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Liquidität & Solvenz 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Bewertung (TTM) 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $67M | $68M | · | $79M | $89M | $96M | · | $101M | $90M | $84M | · | $80M | $75M | $73M | · | $69M | |
| Net Income TTM | $-6M | $-6M | · | $-3M | $-1M | $-1M | · | $-2M | $-7M | $-9M | · | $-11M | $-14M | $-18M | · | $-24M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -30.6 | -4.9 | · | -12.0 | -21.2 | -22.6 | · | -49.6 | -5.9 | -4.0 | · | -3.6 | -5.8 | -1.1 | · | -0.6 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| P / FCF | · | -59.3 | · | · | · | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -19.2 | -35.5 | · | -26.8 | -18.9 | -43.7 | · | 64.2 | 99.1 | -65.1 | · | -34.8 | -31.1 | -16.7 | · | -4.3 | |
| EV / FCF | · | -58.2 | · | · | · | -10.1 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.5 | 0.3 | 0.4 | · | 1.2 | 0.6 | 0.6 | · | 0.8 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -3.3% | -20.2% | · | -8.3% | -4.7% | -4.4% | · | -2.0% | -17.1% | -24.7% | · | -27.9% | -17.2% | -88.4% | · | -181.1% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $69M | $101M | $84M | $73M | $62M |
| Bruttogewinnmarge % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Betriebsgewinnmarge % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Nettoergebnis | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| Verwässerte EPS | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Liquiditätsgrad | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-1M | $3M | — | — | — |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 37 Einreicher · $2.7M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 9 (-2 vs. Vorquartal) | 14 (+9 vs. Vorquartal) | 6 (-2 vs. Vorquartal) | 9 (0 vs. Vorquartal) | +1.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $986.089 | 1.182.361 | 36,75% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $677.668 | 1.229.888 | 25,26% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $197.999 | 359.672 | 7,38% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $169.240 | 288.030 | 6,31% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $128.196 | 232.660 | 4,78% | Aktien |
| Wealthspire Advisors, LLC | $83.587 | 151.838 | 3,12% | Aktien |
| JANE STREET GROUP, LLC | $81.822 | 148.633 | 3,05% | Aktien |
| BlackRock, Inc. | $79.688 | 144.756 | 2,97% | Aktien |
| STATE STREET CORP | $55.548 | 100.904 | 2,07% | Aktien |
| NORTHERN TRUST CORP | $50.570 | 91.862 | 1,88% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $38.179 | 69.353 | 1,42% | Aktien |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27.525 | 50.000 | 1,03% | Aktien |
| LPL Financial LLC | $22.163 | 40.259 | 0,83% | Aktien |
| WealthTrust Axiom LLC | $18.166 | 33.000 | 0,68% | Aktien |
| Spartan Wealth Advisory Services LLC | $13.768 | 25.010 | 0,51% | Aktien |
| TWO SIGMA SECURITIES, LLC | $13.621 | 24.743 | 0,51% | Aktien |
| Tower Research Capital LLC (TRC) | $7.919 | 14.386 | 0,30% | Aktien |
| Burford Brothers, Inc. | $7.799 | 14.168 | 0,29% | Aktien |
| XTX Topco Ltd | $6.157 | 11.184 | 0,23% | Aktien |
| Vanguard Global Advisers, LLC | $5.825 | 10.571 | 0,22% | Aktien |
| Savvy Advisors, Inc. | $5.505 | 10.000 | 0,21% | Aktien |
| WELLS FARGO & COMPANY/MN | $2.753 | 5.000 | 0,10% | Aktien |
| MORGAN STANLEY | $1.091 | 1.982 | 0,04% | Aktien |
| SHP Wealth Management | $782 | 1.421 | 0,03% | Aktien |
| IFG Advisory, LLC | $369 | 670 | 0,01% | Aktien |
| GROUP ONE TRADING LLC | $255 | 463 | 0,01% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0,01% | Aktien |
| OSAIC HOLDINGS, INC. | $150 | 274 | 0,01% | Aktien |
| COMERICA BANK | $136 | 163 | 0,01% | Aktien |
| BARCLAYS PLC | $115 | 209 | 0,00% | Aktien |
| UBS Group AG | $110 | 200 | 0,00% | Aktien |
| FIFTH THIRD BANCORP | $90 | 163 | 0,00% | Aktien |
| GSA CAPITAL PARTNERS LLP | $38 | 69.800 | 0,00% | Aktien |
| Farther Finance Advisors, LLC | $21 | 39 | 0,00% | Aktien |
| Leo H. Evart, Inc. | $8 | 9 | 0,00% | Aktien |
| Richmond Brothers, Inc. | $3 | 6 | 0,00% | Aktien |
| FMR LLC | $3 | 6 | 0,00% | Aktien |
Unternehmensinsider 33 Insider · 17 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | 1. Juli 2026 A | 62.349 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | 4. September 2019 F | 330.056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | 15. Dezember 2017 M | 2.549.907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | 1. Juli 2026 A | 27.239 | 0 | 0 | $0 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | 9. September 2022 A | — | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | 28. November 2019 F | 168.486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | 15. Dezember 2017 M | 671.492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | 1. Juli 2026 A | 28.007 | 0 | 1 | $-3.413 |
| Megan C. Timmins | EVP, CLO & Secretary | 1. Juli 2026 A | 31.240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | 20. Mai 2025 A | 131.035 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | 17. März 2023 A | 25.665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | 17. März 2023 A | 28.515 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | 7. Oktober 2019 F | 576.458 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | 25. April 2019 A | 13.270 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | 25. April 2019 A | 357.970 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | 23. September 2011 A | — | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | 15. Januar 2010 A | — | 0 | 0 | $0 |
| Joseph H Dawson | Direktor | 1. Juli 2026 A | 12.133 | 0 | 0 | $0 |
| Joan Lau | Direktor | 1. Juli 2026 A | 20.944 | 0 | 0 | $0 |
| Robert S Radie | Direktor | 1. Juli 2026 A | 23.985 | 0 | 0 | $0 |
| Allen Nissenson | Direktor | 1. Juli 2026 A | 23.892 | 0 | 0 | $0 |
| John G Cooper | Direktor | 1. Juli 2026 A | 23.670 | 0 | 0 | $0 |
| Andrea Heslin Smiley | Direktor | 20. Mai 2025 A | 142.062 | 0 | 0 | $0 |
| Mark H Ravich | Direktor | 20. Mai 2025 A | 148.831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Direktor | 29. Januar 2020 A | 35.174 | 0 | 0 | $0 |
| Russell H Ellison | Direktor | 9. Januar 2020 A | 10.050 | 0 | 0 | $0 |
| Benjamin Wolin | Direktor | 6. Juni 2019 A | 27.710 | 0 | 0 | $0 |
| Robin L Smith | Direktor | 6. Juni 2019 A | 31.366 | 0 | 0 | $0 |
| Lisa N Colleran | Direktor | 6. Juni 2019 A | 18.674 | 0 | 0 | $0 |
| Patrick J Bagley | Direktor | 19. März 2018 A | 116.307 | 0 | 0 | $0 |
| Ronald D Boyd | Direktor | 19. März 2018 A | 42.678 | 0 | 0 | $0 |
| Kenneth L Holt | Direktor | 16. März 2017 S | 12.630 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | 10%-Eigentümer | 28. Januar 2013 J | 1.360.700 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 15 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 Einreichungen | 6. September 2023 | — | Erste Einreichung | — | SEC |
| Robert L. Chioini ×10 Einreichungen | 29. Dezember 2017 | — | Erste Einreichung | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | 13. August 2013 | — | Erste Einreichung | — | SEC |
| Thomas E. Klema ×3 Einreichungen | 1. Juli 2013 | — | Erste Einreichung | — | SEC |
| Thomas E. Klema (2) | 23. März 2012 | — | Erste Einreichung | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | 8. Dezember 2011 | — | Erste Einreichung | — | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 Einreichungen | 31. März 2011 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 13. Februar 2007 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 13. Februar 2007 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 6. Februar 2006 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 27. Dezember 2005 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 27. Dezember 2005 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 18. Juli 2005 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 22. April 2005 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 23. Januar 2004 | — | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 2 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.